ABIVAX Société Anonyme Balance Sheet Health
Financial Health criteria checks 6/6
ABIVAX Société Anonyme has a total shareholder equity of €126.5M and total debt of €111.1M, which brings its debt-to-equity ratio to 87.9%. Its total assets and total liabilities are €284.5M and €158.0M respectively.
Key information
87.9%
Debt to equity ratio
€111.14m
Debt
Interest coverage ratio | n/a |
Cash | €222.32m |
Equity | €126.47m |
Total liabilities | €158.02m |
Total assets | €284.49m |
Recent financial health updates
Does ABIVAX Société Anonyme (EPA:ABVX) Have A Healthy Balance Sheet?
Oct 03Is ABIVAX Société Anonyme (EPA:ABVX) A Risky Investment?
Apr 24Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?
Jun 07Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?
Jun 06Recent updates
Does ABIVAX Société Anonyme (EPA:ABVX) Have A Healthy Balance Sheet?
Oct 03Is ABIVAX Société Anonyme (EPA:ABVX) A Risky Investment?
Apr 24Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?
Jun 07An Intrinsic Calculation For ABIVAX Société Anonyme (EPA:ABVX) Suggests It's 28% Undervalued
Dec 11Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?
Jun 06A Quick Analysis On ABIVAX Société Anonyme's (EPA:ABVX) CEO Salary
Dec 31Financial Position Analysis
Short Term Liabilities: ABVX's short term assets (€243.0M) exceed its short term liabilities (€80.0M).
Long Term Liabilities: ABVX's short term assets (€243.0M) exceed its long term liabilities (€78.1M).
Debt to Equity History and Analysis
Debt Level: ABVX has more cash than its total debt.
Reducing Debt: ABVX's debt to equity ratio has reduced from 104.2% to 87.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABVX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ABVX has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 34.6% each year.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/27 15:51 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ABIVAX Société Anonyme is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Eric Le Berrigaud | Bryan Garnier & Co |
Oscar Haffen Lamm | Bryan Garnier & Co |
Julian Harrison | BTIG |